Chronic Lymphocytic Leukemia

Why trials studying Chronic Lymphocytic Leukemia stopped, in this sample of ClinicalTrials.gov.

25 stopped trials with a clear reason; 92% ended for non-scientific reasons.

Trials

• Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
  NCT05317936 · TERMINATED · slow accrual
  “\<75% participation”
• Early Intervention With Acalabrutinib in Patients With High Risk CLL
  NCT04660045 · WITHDRAWN · funding business
  “Company supplying drug/funding ceased support.”
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
  NCT04553692 · TERMINATED · funding business
  “Study terminated due strategic corporate pivot to focus on auto-immune indications”
• FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
  NCT04245722 · TERMINATED · funding business
  “The study was terminated by the Sponsor.”
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  NCT04163718 · TERMINATED · manufacturing supply
  “Drug no longer available”
• Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
  NCT03514017 · TERMINATED · funding business
  “Funding unavailable”
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
  NCT03801525 · TERMINATED · funding business
  “Strategic/Business decision”
• Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
  NCT03370185 · WITHDRAWN · funding business
  “Reassessing corporate priorities.”
• Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
  NCT03153514 · TERMINATED · slow accrual
  “Prematurely terminated due to poor accrual”
• Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
  NCT02784834 · TERMINATED · funding business
  “lack of funding”
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
  NCT02656303 · TERMINATED · funding business
  “Strategic/Business Decision”
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
  NCT01163201 · WITHDRAWN · other
  “Replaced by a new study”
• Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
  NCT01799889 · TERMINATED · funding business
  “Sponsor's decision to discontinue development of entospletinib.”
• Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
  NCT01069432 · WITHDRAWN · funding business
  “IRB delayed their review for an extensive period of time. Funding for this protocol is no longer available.”
• Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
  NCT01010568 · TERMINATED · slow accrual
  “Unable to accrue patients due to change in standard CLL therapy”
• Pilot Study of Unrelated Cord Blood Transplantation
  NCT00916045 · TERMINATED · slow accrual
  “Recruitment issues”
• A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
  NCT00949988 · TERMINATED · slow accrual
  “Three subjects were enrolled and all three subjects withdrew.”
• A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
  NCT00829647 · WITHDRAWN · slow accrual
  “Unable to enroll”
• Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
  NCT00800566 · WITHDRAWN · funding business
  “Sponsor terminated.”
• Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
  NCT00758693 · WITHDRAWN · slow accrual
  “Funding was withdrawn due to insufficient accrual”
• Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
  NCT00899353 · TERMINATED · logistics pi
  “Original Principal Investigator left the institution.”
• In-Vivo Activated T-Cell Depletion to Prevent GVHD
  NCT00594308 · TERMINATED · futility
  “Treatment ineffective”
• Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
  NCT00596336 · TERMINATED · slow accrual
  “Recruitment issues”
• Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
  NCT00183950 · TERMINATED · funding business
  “No funding”
• Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
  NCT00234481 · TERMINATED · slow accrual
  “Study closed due to slow enrollment”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.